Nat commun: a new method to enhance the anti-cancer immune response

February 11, 2020 Dr BIOON / -- Christopher E Rudd, a researcher at the University of Montreal, has found a new cell therapy that can enhance the immune response of T lymphocytes to malignant tumors Dr Christopher E Rudd is a professor in the Department of Microbiology, infection and immunology at the University of Montreal and director of the cell signal transduction project in the cr-hmr immunotherapy department The results of this study were recently published in nature communications Photo source: nature communications Rudd said: "our work has found a new T-cell protein that interacts with key receptors that detect and respond to cancer antigens We used these findings to develop a new form of immunotherapy in which T cells are overactivated to allow them to penetrate and attack tumors This finding suggests that regulating the recognition of proteins can activate the immune system, leading to the destruction of cancer cells "To date, the efficacy of this new immunotherapy for leukemia and certain skin cancers has been demonstrated in animals The next phase will be human clinical trials "This discovery is a scientific breakthrough that will significantly enhance the effectiveness of the immune system in killing cancer cells," said Dr Denis Claude Roy, director of science and medicine at the center for excellence in cell therapy and cr-hmr Finally, this method can also improve the effectiveness of car-t cell therapy, which is currently being used in the hospital Maisonneuve Rosemont Reference materials: young Raj Thaker et al, GTPase activating protocol RASAL1 associates with ZAP-70 of the TCR and indirectly regulated T-cell membrane immunity, nature communications (2019) Doi: 10.1038/s41467-019-12544-4